Overview of Semaglutide and Tirzepatide
Semaglutide and tirzepatide are injectable medications used to treat type 2 diabetes. More recently, they have also been used off-label for chronic weight management. Both belong to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists.
Ozempic (semaglutide) was approved by the FDA in 2017, while Wegovy and Zepbound are higher dose formulations of semaglutide approved in 2021 and 2022 specifically for weight loss. Mounjaro (tirzepatide) was approved in 2022.
How They Work
Semaglutide and tirzepatide work by mimicking the effects of GLP-1, a hormone that helps control blood sugar and appetite. They activate GLP-1 receptors, which:
- Stimulate the release of insulin when blood sugar is high
- Suppress the release of glucagon when blood sugar is low
- Slow digestion to reduce food intake and support weight loss
Approved Uses
Ozempic is approved for treating type 2 diabetes, along with diet and exercise. Higher dose semaglutide (Wegovy, Zepbound) is specifically approved for chronic weight management.
Mounjaro is approved as both a diabetes and weight loss medication. In clinical trials, it showed improved blood sugar control compared to Ozempic and greater weight loss compared to Wegovy.
Side Effects of Semaglutide vs Tirzepatide
As injectable diabetes and weight loss medications, semaglutide and tirzepatide have some similar side effects. However, there are also key differences in their safety profiles.
Common Side Effects
The most common side effects of semaglutide and tirzepatide include:
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
- Stomach pain
- Constipation
- Dizziness
- Fatigue
These side effects are usually mild to moderate and tend to go away with continued treatment. Taking the medication with food can help minimize gastrointestinal issues.
Differences in Side Effect Risks
While semaglutide and tirzepatide share many common side effects, some key differences in their safety profiles include:
- Thyroid Problems: Thyroid cell tumors were seen in rodent studies with tirzepatide. No increased risk of thyroid cancer has been seen with semaglutide, but it may cause thyroid nodules and changes in thyroid function tests.
- Kidney Issues: Tirzepatide may increase risk of kidney dysfunction. Cases of kidney injury and failure have also been reported rarely with semaglutide.
- Vision Changes: Tirzepatide may cause vision changes, particularly among those with diabetes retinopathy. Semaglutide is not known to impact vision.
- Allergic Reactions: Hypersensitivity reactions have occurred rarely with both medications. However, anaphylaxis appears more common with tirzepatide.
In clinical trials, tirzepatide had higher rates of several gastrointestinal side effects like nausea, vomiting, diarrhea, and constipation. The rate of discontinuation due to side effects was also higher compared to Ozempic trials.
Risk Evaluation
In most cases, the benefits of improved diabetes and weight control will outweigh potential risks of semaglutide and tirzepatide side effects. However, benefits and risks should be carefully evaluated for each individual.
Those with conditions like thyroid cancer, multiple endocrine neoplasia syndrome, kidney problems, diabetic retinopathy, and gallbladder disease may have increased risks that need special consideration.
Abuse and Safety Issues with Compounded Forms
Due to high costs and limited approval for weight loss, there has been growing interest in compounded forms of semaglutide and tirzepatide.
What is Compounding?
Compounding refers to making customized medications by mixing ingredients to create specific doses or formulas. Compounding pharmacies prepare these customized medications.
Low Cost but Lacking Safeguards
Compounded semaglutide and tirzepatide have not gone through FDA approval. They offer big savings compared to brand name Ozempic, Wegovy, Mounjaro and more flexibility in dosing regimens.
However, quality varies widely between pharmacies. Using compounded medications also forgoes safeguards in place for approved drugs like clinical trial data, regulation, quality oversight, and product monitoring.
Abuse Potential
Accessibility, affordability and variability of compounded semaglutide and tirzepatide raise concerns about inappropriate use and abuse. Without oversight, some may use dangerously high doses, risky combinations with other drugs, or get medication without proper health screening.
This could increase serious risks like hypoglycemia, ketoacidosis, kidney problems, vision issues, pancreatitis, suicidal thoughts, and other psychiatric side effects.
Safe and Effective Use of Semaglutide and Tirzepatide
When used appropriately under medical supervision, semaglutide and tirzepatide offer substantial health benefits for many people with obesity, prediabetes or type 2 diabetes. However, some key practices can promote safe and effective use.
Medical Prescriptions and Monitoring
Starting semaglutide or tirzepatide should always involve a prescription and oversight from a knowledgeable medical provider. Baseline health screening and regular monitoring helps mitigate risks and maximize benefits.
FDA-Approved Brand Name Products
Opting for Ozempic, Wegovy, or Mounjaro ensures you are getting an rigorously tested, high quality therapeutic product. The reliability and safety data for brands outweighs potential savings from compounded alternatives.
Following Dosing Guidelines
Carefully increasing doses and using these injectables as prescribed is important to control side effects and prevent complications. Even small overdoses can exponentially increase health risks.
Never use semaglutide or tirzepatide prescribed for someone else. Do not increase your dose or frequency without consulting your provider.
While compounded GLP-1 drugs offer savings for weight loss, the risks of inappropriate use, unknown side effects, and lack of quality controls make FDA-approved brands like Ozempic, Wegovy and Mounjaro better options for most people. Using either medication safely requires disciplined medical oversight and dosing.
FAQs
What are the most common side effects of semaglutide and tirzepatide?
The most common side effects of both medications include nausea, vomiting, diarrhea, stomach pain, decreased appetite, constipation, dizziness and fatigue. These are usually mild and tend to decrease over time.
Does tirzepatide cause more side effects than semaglutide?
In clinical trials, tirzepatide had higher rates of certain gastrointestinal side effects like nausea, vomiting and diarrhea. The rate of people stopping treatment due to side effects was also higher compared to semaglutide trials.
Is taking compounded semaglutide or tirzepatide dangerous?
Compounded versions of these drugs lack FDA quality oversight and clinical safety data. This raises risks around inappropriate use, uncertain side effects, unsafe dosing, and possible impurities. FDA approved brands like Ozempic and Mounjaro are safer options.
What can I do to use these medications more safely?
Using semaglutide or tirzepatide safely requires getting an FDA approved brand with a prescription, having a doctor monitor your health, starting with low doses, and carefully increasing doses per prescribing guidelines.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a healthcare professional before starting any new treatment regimen.
Add Comment